Marcia S. Brose

Marcia S. Brose, MD, PhD is Professor of Oncology and Director of the Center for Rare Cancers and Personalized Therapy at Sidney Kimmel Cancer Center, Thomas Jefferson University. She is internationally recognized as one of the foremost experts in thyroid cancer pharmacology and targeted therapy, with landmark contributions to the clinical development of sorafenib and lenvatinib for radioiodine-refractory differentiated thyroid cancer (RAI-refractory DTC). Her translational research integrates molecular oncology with precision medicine to identify actionable targets in thyroid and other rare cancers. Dr. Brose served as a principal investigator for DECISION, the phase III trial that established sorafenib as the first approved targeted therapy for RAI-refractory DTC, published in The Lancet in 2014. She has also led and contributed to SELECT and subsequent studies evaluating lenvatinib, cabozantinib, and novel combination regimens in thyroid cancer, building a comprehensive framework for sequencing kinase inhibitors in this disease. Her research has defined biomarker strategies for treatment selection in RAI-refractory thyroid cancer. Beyond thyroid cancer, Dr. Brose has contributed to the molecular characterization of rare solid tumors and leads one of the most active rare cancer clinical trials programs in the United States. She has authored over 200 peer-reviewed publications and is a frequent invited faculty member at ASCO, ESMO, and the American Thyroid Association annual meetings.